NDC 82922-021 - Truemed Group LLC
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 82922-021
- Package NDCs from labels
- 82922-021-01
- Manufacturer
- Truemed Group LLC
- Effective date
- 2022-08-10
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| PIRFENIDONE - Truemed Group LLC | Truemed Group LLC | 2022-08-10 | HUMAN PRESCRIPTION DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Pirfenidone | PIRFENIDONE | Aurobindo Pharma Limited | 3115f15f-171c-4266-8dc8-5655f56e6acc | 2026-04-22 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | AvKARE | 07ff87b3-0a88-15b4-e063-6294a90a72ab | 2026-01-14 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | AvKARE | 08046b49-a8b3-a78d-e063-6394a90a80fa | 2026-01-14 | Warnings, Adverse reactions | D7NLD2JX7U |
| PIRFENIDONE | PIRFENIDONE | Accord Healthcare Inc. | fab59395-1c5d-4c64-ba47-34d75736e983 | 2025-12-17 | Warnings, Adverse reactions | D7NLD2JX7U |
| ESBRIET | PIRFENIDONE | Genentech, Inc. | 2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e | 2025-12-05 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Golden State Medical Supply, Inc. | 1b3261fe-c066-6e86-e063-6294a90a675c | 2025-11-24 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Bryant Ranch Prepack | 33f1ca21-4c08-4103-889d-1d9c929b5fad | 2025-10-30 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Bryant Ranch Prepack | bd3483bf-96e9-4d6b-a844-63bd002c48a4 | 2025-10-30 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | ANI Pharmaceuticals, Inc. | 976620bb-c10e-4b13-8a97-7025fda6b7d5 | 2025-09-17 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Aurobindo Pharma Limited | 50958060-c904-4374-997d-59df54007fa4 | 2025-08-13 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Bryant Ranch Prepack | bfcb3157-cfa1-493d-9598-1e7fd3d355d9 | 2025-08-07 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Bryant Ranch Prepack | 9bdc7ed9-e51c-4101-a792-31619f05136b | 2025-08-07 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Laurus Labs Limited | 29b0fd0e-5a2b-4da7-8524-177dc28bf55e | 2025-07-22 | Warnings, Adverse reactions | D7NLD2JX7U |
| ESBRIET | PIRFENIDONE | Legacy Pharma USA Inc. | 81f17f7d-cb04-4052-8682-dd3e330210ab | 2025-06-09 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Micro Labs Limited | 1abc06c7-6a45-4a0b-b2da-c228aaa137ed | 2025-06-04 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Amneal Pharmaceuticals NY LLC | 94362a07-7c64-42ce-adef-f49585af55d6 | 2025-05-30 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone Capsule, 267 mg | PIRFENIDONE CAPSULE, 267 MG | Macleods Pharmaceuticals Limited | 3e8acd31-bbc7-48d5-956d-6cb04cbdc96c | 2025-03-28 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Amneal Pharmaceuticals NY LLC | 1d4d7aa2-1248-4639-baf5-5e2ae72cbcd8 | 2025-02-28 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Amneal Pharmaceuticals NY LLC | ea26490e-fd32-4807-8556-eb6f5f963c23 | 2024-11-04 | Warnings, Adverse reactions | D7NLD2JX7U |
| Pirfenidone | PIRFENIDONE | Sandoz Inc | 945d4337-7d18-4d84-807b-8ae13750c76d | 2024-10-30 | Warnings, Adverse reactions | D7NLD2JX7U |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.